High-dose administration of levofloxacin (LVFX) in the treatment of acute exacerbation of chronic otitis media

Kazunori Nishizaki, Hirofumi Akagi, Kunihiro Fukushima, Yu Masuda, Manabu Maeta, Yasushi Takeda, Toshiaki Ogawara, Shin Kariya, Seiko Akagi, Hiroyuki Teshima, Kaori Shirakami

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Thirty-two adult cases of acute exacerbation of chronic otitis media (COM) were treated by high-dose (600 mg/day) oral administration of levofloxacin (LVFX). Clinically, 27 COM cases (84.4%) were effectively treated, and no apparent side effects were noted during this study protocol. Among 31 clinically isolated strains whose therapeutic outcomes were bacteriologically confirmed, 28(90%) strains were not detectable after high- dose LVFX treatment. Bacteriological therapeutic failures in the treatment were observed in three COM patients with MRSA and a patient with coagulase- negative staphylococci. High-dose administration of LVFX was effective in the treatment of acute exacerbation of COM except in cases that were caused by drug resistant staphylococci.

Original languageEnglish
Pages (from-to)77-84
Number of pages8
JournalPractica Otologica
Volume93
Issue number1
DOIs
Publication statusPublished - 2000

Keywords

  • Chronic otitis media
  • Levofloxacin (LVFX)
  • MRSA

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'High-dose administration of levofloxacin (LVFX) in the treatment of acute exacerbation of chronic otitis media'. Together they form a unique fingerprint.

Cite this